Can Losartan Be Used in CKD Stage 3?
Yes, losartan can and should be used in patients with CKD stage 3, particularly when albuminuria is present, and should be continued even as eGFR declines below 30 mL/min/1.73 m².
Primary Recommendation
The 2024 KDIGO guidelines explicitly state that ARBs like losartan should be continued in CKD patients even when eGFR falls below 30 mL/min/1.73 m² 1. This directly addresses CKD stage 3 (eGFR 30-59 mL/min/1.73 m²) and confirms losartan is appropriate throughout this stage and beyond.
When to Use Losartan in CKD Stage 3
Strong indications (Grade 1B recommendations):
- With diabetes + moderately-to-severely increased albuminuria (A2 or A3) 1
- Without diabetes + severely increased albuminuria (A3) 1
- Hypertension requiring treatment (BP ≥140/90 mmHg) 2
Weaker but reasonable indications (Grade 2C):
- Without diabetes + moderately increased albuminuria (A2) 1
- Hypertension or heart failure with reduced ejection fraction, even without significant albuminuria 1
Dosing in CKD Stage 3
No dose adjustment is required for renal impairment alone 3. The FDA label does not restrict losartan use based on eGFR:
- Start with 50 mg once daily for most patients
- Can increase to 100 mg once daily as needed for blood pressure control
- Use 25 mg once daily only if volume-depleted (e.g., on high-dose diuretics) 3
Research supports that even 50 mg daily is effective and safe in CKD stage 3 patients, showing renoprotection without adverse effects 4.
Critical Monitoring Requirements
Check within 2-4 weeks of initiation or dose increase 1:
- Serum creatinine
- Serum potassium
- Blood pressure
Acceptable changes:
- Continue therapy if creatinine rises ≤30% within 4 weeks 1
- This initial rise is expected and does not indicate harm
Stop or reduce dose only if:
- Creatinine rises >30% within 4 weeks 1
- Uncontrolled hyperkalemia despite potassium-lowering measures 1
- Symptomatic hypotension 1
- eGFR <15 mL/min/1.73 m² with uremic symptoms 1
Managing Hyperkalemia Without Stopping Losartan
Hyperkalemia should be managed with potassium-lowering strategies rather than discontinuing losartan 1. This is a critical practice point because the renoprotective benefits often outweigh the inconvenience of managing potassium levels. Options include:
- Dietary potassium restriction
- Diuretics (if appropriate)
- Potassium binders
- Sodium bicarbonate (if acidotic)
Notably, one study found that high dietary potassium intake may actually reduce losartan's antiproteinuric effect, suggesting moderate potassium intake optimization may help 5.
Evidence of Benefit in CKD Stage 3
A prospective randomized trial specifically in normotensive patients with stage 3 CKD showed that losartan 50 mg daily:
- Significantly reduced proteinuria (1.72 to 0.99 g/day, P<0.001)
- Stabilized eGFR over 12 months (44.8 to 44.1 mL/min/1.73 m², P=0.120)
- Was well-tolerated without blood pressure changes 4
Another study in hypertensive stage 3 CKD patients demonstrated that losartan (with or without hydrochlorothiazide) was effective and safe, with stable renal function throughout treatment 6.
Combination Therapy Considerations
Adding low-dose hydrochlorothiazide (12.5 mg) to losartan 50 mg provides superior blood pressure control and proteinuria reduction compared to increasing losartan to 100 mg alone in stage 3 CKD 7, 8. This combination is particularly effective when BP remains above target.
Never combine losartan with ACE inhibitors or direct renin inhibitors - this is explicitly contraindicated (Grade 1B) 1.
Common Pitfalls to Avoid
- Don't stop losartan prematurely for mild creatinine rises - up to 30% increase is acceptable and expected 1
- Don't discontinue for hyperkalemia without trying management strategies first 1
- Don't assume dose reduction is needed in CKD stage 3 - full doses provide maximum benefit 1
- Don't withhold in normotensive patients with significant proteinuria - renoprotection occurs independent of BP lowering 4
Bottom Line
Losartan is not only safe in CKD stage 3 but is actively recommended by the highest quality 2024 guidelines, particularly when albuminuria is present. The key is appropriate monitoring and managing side effects proactively rather than discontinuing this renoprotective medication.